Long Term and Oncologic Outcomes for Patients Receiving Piperacillin-Tazobactam or Cefoxitin as Antibiotic Prophylaxis for Pancreatoduodenectomy
While patients experiencing an SSI had poorer survival, piperacillin-tazobactam prophylaxis did not significantly affect oncologic care delivery. These results cement the long-term implications of perioperative complications in patients with cancer and highlight leveraging cancer registries for clinical trial data analysis.
Authors
- C. Ko (ORCID: https://orcid.org/0000-0001-7639-4083)
- Vanessa Thompson (ORCID: https://orcid.org/0000-0003-0431-4923)
- Kelley Chan (ORCID: https://orcid.org/0009-0006-1579-2428)
- Adam C. Yopp (ORCID: https://orcid.org/0000-0002-5887-5315)
- Bryan E. Palis
- Michael I. D’Angelica
- Henry A. Pitt
- Ryan J. Ellis
Institutions
- Rutgers, The State University of New Jersey (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of California, Los Angeles (US)
- VA Greater Los Angeles Healthcare System (US)
- Rutgers Cancer Institute (US)
- Indiana University – Purdue University Indianapolis (US)
- The University of Texas Southwestern Medical Center (US)
- American College of Surgeons (US)
Publication Details
- Journal
- Annals of Surgery
- Published
- 2026-02-24
- DOI
- https://doi.org/10.1097/sla.0000000000007031
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00